This study says that inflammatory events in the CNS are important for progression, I say NSS!
Intrathecal, Not Systemic Inflammation Is Correlated With Multiple Sclerosis Severity, Especially in Progressive Multiple Sclerosis. Milstein JL, Barbour CR, Jackson K, Kosa P, Bielekova B. Front Neurol. 2019 Nov 22;10:1232. doi: 10.3389/fneur.2019.01232. eCollection 2019
Objective: To test the hypothesis that Multiple Sclerosis (MS) patients have increased peripheral inflammation compared to healthy donors and that this systemic activation of the immune system, reflected by acute phase reactants (APRs) measured in the blood, contributes to intrathecal inflammation, which in turn contributes to the development of disability in MS. Methods: Eight serum APRs measured in a prospectively-collected cross-sectional cohort with a total of 51 healthy donors and 291 untreated MS patients were standardized and assembled into related biomarker clusters to derive global measures of systemic inflammation. The resulting APR clusters were compared between diagnostic categories and correlated to equivalently-derived cerebrospinal fluid (CSF) biomarkers of innate and adaptive immunity. Finally, correlations were calculated between biomarkers of systemic and intrathecal inflammation and MS severity measures, which predict future rates of disability progression. Results: While two blood APR clusters were elevated in MS patients, only one exhibited a weak correlation with MS severity. All CSF inflammation clusters, except CSF albumin, correlated with at least one measure of MS severity, with biomarkers of humoral adaptive immunity exhibiting the strongest correlations, especially in Progressive MS. Conclusion: Systemic inflammation does not appear to be strongly associated with intrathecal inflammation in MS. Positive correlations between markers of intrathecal inflammation, especially of humoral immunity, with MS severity measures support a pathogenic role of intrathecal (compartmentalized) inflammation in central nervous system tissue destruction, including in Progressive MS.
“Systemic inflammation does not appear to be strongly associated with intrathecal inflammation in MS”
Why them Alemtuzumab is so efficacious?
Alemtuzumab kills most of te Systemic inflammation but does not enter cns
Obrigado
because when it is used early there is more limited persistent CNS inflammation when it is used late when there is persistent neurodegenerative inflammation, clinical signs continue to worsen (Coles et al. 1999).
Obviously the system inflammation feeds into generating the persistent CNS
de nada
🙂
Caneco
Finalmente
Been asking this for so long
Ok but you know (better than me) that timing that early cns inflamatory events its very dificult
Also some people present with more cns inflamation than others (damage cell in the cns)
And some years ago i came to see Dr David Baker video saying that ms its neurodegenerative from the get go
Maybe thats only part of the story
Thanks again
“Systemic inflammation does not appear to be strongly associated with intrathecal inflammation in MS”
I didnt say this, I said no shit sherlock
Yes Ms is neurodegeneratative from the get do and it is inflammatory from the get go until the end, system inflammation is part of the story as is CNS inflammation
“Systemic inflammation does not appear to be strongly associated with intrathecal inflammation in MS”
I didnt say this, I said no shit sherlock
Yes Ms is neurodegeneratative from the get do and it is inflammatory from the get go until the end, system inflammation is part of the story as is CNS inflammation
Is all of this inflammation measured via spinal taps? Thank-you.